CTI BioPharma Corp. (NASDAQ:CTIC) will be discussing 3Q20 financial results with the investment community.on 10th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.ctibiopharma.com
Earnings Expectation
CTI BioPharma Corp. is reporting third quarter financial results on Tuesday 10th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, CTIC is expected to report 3Q20 loss of $ 0.15 per share from revenue of $ 0.00 million. For the full year, analysts anticipate top line of $ 0.00 million, while looking forward to loss of $ 0.69 per share bottom line.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited.